Lymphoma Clinical Trials in Detroit

Showing 361-380 of 546 trials

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

NCT03119467

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas

Rhizen Pharmaceuticals SA21 participantsStarted May 2017

Birmingham, Alabama, United States • Duarte, California, United States • Aurora, Colorado, United States +8 more locations

COMPLETEDPhase 3< 1 mile

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707

The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Relapsed or Refractory Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Pharmacyclics LLC.391 participantsStarted Jun 2012

La Jolla, California, United States • Los Angeles, California, United States • Santa Maria, California, United States +73 more locations

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Lymphoma Trials in Other Cities

The Second Multicenter Hemophilia Cohort Study

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Other Conditions in Detroit